Trials / Completed
CompletedNCT03776123
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients Based on "Guideline for Re-examination of New Drugs"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 347 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.
Conditions
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2024-03-26
- Completion
- 2024-03-26
- First posted
- 2018-12-14
- Last updated
- 2024-05-29
Locations
47 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03776123. Inclusion in this directory is not an endorsement.